Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of “Moderate Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned an average rating of “Moderate Buy” from the twelve research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $25.4444.

A number of equities research analysts have commented on ARCT shares. B. Riley Financial started coverage on shares of Arcturus Therapeutics in a research report on Wednesday, March 18th. They issued a “buy” rating and a $22.00 target price for the company. Weiss Ratings raised shares of Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, April 21st. Piper Sandler cut their target price on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Finally, Citigroup cut their target price on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, March 5th.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. grew its position in Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 738 shares during the period. CANADA LIFE ASSURANCE Co grew its position in Arcturus Therapeutics by 27.5% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,567 shares during the period. Bank of America Corp DE grew its position in Arcturus Therapeutics by 0.7% in the 2nd quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock worth $3,805,000 after purchasing an additional 2,098 shares during the period. BNP Paribas Financial Markets grew its position in Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,586 shares during the period. Finally, Two Sigma Investments LP grew its position in Arcturus Therapeutics by 3.3% in the 3rd quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company’s stock worth $1,644,000 after purchasing an additional 2,857 shares during the period. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Up 0.9%

Shares of ARCT opened at $6.88 on Friday. The company has a market capitalization of $195.53 million, a P/E ratio of -2.45 and a beta of 2.36. The firm has a 50 day moving average of $7.78 and a 200 day moving average of $7.47. Arcturus Therapeutics has a twelve month low of $5.85 and a twelve month high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.08. The company had revenue of $2.06 million during the quarter, compared to the consensus estimate of $6.30 million. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. On average, sell-side analysts expect that Arcturus Therapeutics will post -3.99 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.